ReviewNature reviews. Drug discovery2018
Interleukin-6: designing specific therapeutics for a complex cytokine.
Review in Nature reviews. Drug discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 359 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
359 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials.BMC endocrine disorders · 2023Pooled it
- Dynamic salivary cytokine profile of recurrent aphthous stomatitis patients in thalidomide maintenance treatment.Clinical oral investigations · 2024Trial
- A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.Med (New York, N.Y.) · 2022Trial
- Comment on "soluble cytokine receptor levels in obstructive sleep apnea patients treated with continuous positive airway pressure therapy".Future science OA · 2026Article
- Selective inhibition of IL-6 trans-signalling reveals distinct mechanisms of human classic and trans-signalling receptor-complex formation.Communications biology · 2026Article
- Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.Nature reviews. Drug discovery · 2026Review
- Interleukin-39 is a Prognostic Biomarker and Therapy Target for Sepsis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ellagic acid regulates astrocytic responses under inflammatory conditions in primary astrocyte cultures: effects on oxidative stress, inflammatory cytokines, and glycogen synthase kinase-3β.Molecular biology reports · 2026Article
- Quantum and nanoscale sensing of microinflammation for earlier detection of chronic inflammatory and neuroimmune disease.Discover nano · 2026Review
- Mendelian Randomization Reveals Interleukin-6 Receptor-Lipoprotein(a) Interplay With Independent Cardiovascular Risk Reductions.JACC. Basic to translational science · 2026Article
- Targeting Inflammation in Atherosclerosis: Mechanistic Rationale, Clinical Trials, and Regulatory Considerations.Reviews in cardiovascular medicine · 2026Review
- Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease.Materials today. Bio · 2026Article
- The Immune System as a Proarrhythmic Mediator: A Novel Paradigm for the Development of New Antiarrhythmic Therapy.The Canadian journal of cardiology · 2026Review
- Risk factors analysis of poor prognosis in ICU-admitted children with severe influenza pneumonia: a retrospective case-control study.Italian journal of pediatrics · 2026Article
- Yam Protects Immunocompromised Mice from Influenza Infection via the Gut-SCFA-GPCR-Immune Axis.Nutrients · 2026Article
- The interplay between cytokine genes and microRNAs in anemia of inflammation among hemodialysis patients.Scientific reports · 2026Article
- Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Oncostatin M receptor deficiency as a novel candidate genetic cause of autosomal recessive hyper-IgE syndrome.Journal of human immunity · 2026Article
- Extracellular vesicle engineering using a small scaffold protein.Nature communications · 2026Article
- An Advanced 3D Model of Vascularized Epithelial Ovarian Cancer in a Tumor-on-a-Chip System Based on Multi-Cell Culture.Sensors (Basel, Switzerland) · 2026Article
299 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a pivotal cytokine with a diverse repertoire of physiological functions that include regulation of immune cell proliferation and differentiation. Dysregulation of IL-6 signalling is associated with inflammatory and lymphoproliferative disorders such as rheumatoid arthritis and Castleman disease, and several classes of therapeutics have been developed that target components of the IL-6 signalling pathway. So far, monoclonal antibodies against IL-6 or IL-6 receptor (IL-6R) and Janus kinases (JAK) inhibitors have been successfully developed for the treatment of autoimmune diseases such as rheumatoid arthritis. However, clinical trials of agents targeting IL-6 signalling have also raised questions about the diseases and patient populations for which such agents have an appropriate benefit-risk profile. Knowledge from clinical trials and advances in our understanding of the complexities of IL-6 signalling, including the potential to target an IL-6 trans-signalling pathway, are now indicating novel opportunities for therapeutic intervention. In this Review, we overview the roles of IL-6 in health and disease and analyse progress with several approaches of inhibiting IL-6-signalling, with the aim of illuminating when and how to apply IL-6 blockade.
Indexed as
Identifiers
29725131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.